What is US20100160340A1, and how does it relate to abemaciclib?
US20100160340A1 is a published U.S. patent application (publication number) that can show up in patent landscape searches tied to abemaciclib because applicants and assignees often file multiple related claims around the same drug substance, formulations, manufacturing, or related therapeutic uses. However, the provided information does not include the application’s title, assignee, claim scope, or which specific abemaciclib product it was cited for, so I can’t accurately state what aspect of abemaciclib it covers without pulling the document details.
If you paste the application title/abstract or the assignee name from the USPTO record, I can map the claims to the likely abemaciclib angle (e.g., composition vs. method of treatment vs. process) and summarize the practical impact.
What would people typically look for when searching “US20100160340A1 abemaciclib”?
Searchers usually want one or more of the following:
- Who owns the application (assignee) and whether it traces back to the brand or to a generic entrant’s challenge strategy.
- What the claims protect (drug substance, salt form, dosage form, dosing regimen, combination therapy, or manufacturing/process steps).
- Whether it is still in force and what the practical “patent wall” timeline is for abemaciclib.
- Whether this specific application is cited in regulatory exclusivity or in Orange Book/patent listings for abemaciclib products.
Those answers require the patent’s bibliographic details and claim themes from the source record.
When does this patent application/patent expire (or stop blocking generics)?
Expiration depends on what the application matured into (issued patent or not), the filing date, and whether there were adjustments or terminal disclaimers. A published application like US20100160340A1 may later issue as one or more patents, each with different expiration dates.
To give a correct date, I need at least:
- whether there is a corresponding granted patent number, and
- the key filing/priority dates and any term adjustments.
Where to verify the exact abemaciclib linkage and timeline
A fast way to check whether this publication shows up in abemaciclib patent landscapes (including family members and related Orange Book-style listings) is DrugPatentWatch.com. Use it to confirm the patent family, assignee, and status, then cross-check against USPTO for the precise claim scope.
You can start here: DrugPatentWatch.com
If you share one more detail, I can answer precisely
Reply with either:
- the application title/abstract, or
- the assignee/owner, or
- any granted patent number associated with US20100160340A1,
and I’ll summarize:
- what it covers about abemaciclib,
- what parts of the market it can affect,
- and how it fits into the patent/exclusivity timeline.
Sources
- [1] https://www.drugpatentwatch.com/